eLife (Jul 2021)
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
- Nikhil Faulkner,
- Kevin W Ng,
- Mary Y Wu,
- Ruth Harvey,
- Marios Margaritis,
- Stavroula Paraskevopoulou,
- Catherine Houlihan,
- Saira Hussain,
- Maria Greco,
- William Bolland,
- Scott Warchal,
- Judith Heaney,
- Hannah Rickman,
- Moria Spyer,
- Daniel Frampton,
- Matthew Byott,
- Tulio de Oliveira,
- Alex Sigal,
- Svend Kjaer,
- Charles Swanton,
- Sonia Gandhi,
- Rupert Beale,
- Steve J Gamblin,
- John W McCauley,
- Rodney Stuart Daniels,
- Michael Howell,
- David Bauer,
- Eleni Nastouli,
- George Kassiotis
Affiliations
- Nikhil Faulkner
- Retroviral Immunology, London, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United Kingdom
- Kevin W Ng
- ORCiD
- Retroviral Immunology, London, United Kingdom
- Mary Y Wu
- ORCiD
- High Throughput Screening STP, London, United Kingdom
- Ruth Harvey
- Worldwide Influenza Centre, London, United Kingdom
- Marios Margaritis
- Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom
- Stavroula Paraskevopoulou
- Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom
- Catherine Houlihan
- Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom; Division of Infection and Immunity, London, United Kingdom
- Saira Hussain
- Worldwide Influenza Centre, London, United Kingdom; RNA Virus Replication Laboratory, London, United Kingdom
- Maria Greco
- RNA Virus Replication Laboratory, London, United Kingdom
- William Bolland
- Retroviral Immunology, London, United Kingdom
- Scott Warchal
- High Throughput Screening STP, London, United Kingdom
- Judith Heaney
- Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom
- Hannah Rickman
- Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom
- Moria Spyer
- Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom; Department of Population, Policy and Practice, London, United Kingdom
- Daniel Frampton
- Division of Infection and Immunity, London, United Kingdom
- Matthew Byott
- Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom
- Tulio de Oliveira
- School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa; Department of Global Health, University of Washington, Seattle, United States
- Alex Sigal
- ORCiD
- School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; Africa Health Research Institute, Durban, South Africa; Max Planck Institute for Infection Biology, Berlin, Germany
- Svend Kjaer
- ORCiD
- Structural Biology STP, London, United Kingdom
- Charles Swanton
- Cancer Evolution and Genome Instability Laboratory, London, United Kingdom
- Sonia Gandhi
- Neurodegradation Biology Laboratory, London, United Kingdom
- Rupert Beale
- ORCiD
- Cell Biology of Infection Laboratory, London, United Kingdom
- Steve J Gamblin
- Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, United Kingdom
- John W McCauley
- ORCiD
- Worldwide Influenza Centre, London, United Kingdom
- Rodney Stuart Daniels
- Worldwide Influenza Centre, London, United Kingdom
- Michael Howell
- High Throughput Screening STP, London, United Kingdom
- David Bauer
- RNA Virus Replication Laboratory, London, United Kingdom
- Eleni Nastouli
- Retroviral Immunology, London, United Kingdom; Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom; Department of Population, Policy and Practice, London, United Kingdom
- George Kassiotis
- ORCiD
- Retroviral Immunology, London, United Kingdom; Department of Infectious Disease, St Mary's Hospital, Imperial College London, London, United Kingdom
- DOI
- https://doi.org/10.7554/eLife.69317
- Journal volume & issue
-
Vol. 10
Abstract
Background: The degree of heterotypic immunity induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains is a major determinant of the spread of emerging variants and the success of vaccination campaigns, but remains incompletely understood. Methods: We examined the immunogenicity of SARS-CoV-2 variant B.1.1.7 (Alpha) that arose in the United Kingdom and spread globally. We determined titres of spike glycoprotein-binding antibodies and authentic virus neutralising antibodies induced by B.1.1.7 infection to infer homotypic and heterotypic immunity. Results: Antibodies elicited by B.1.1.7 infection exhibited significantly reduced recognition and neutralisation of parental strains or of the South Africa variant B.1.351 (Beta) than of the infecting variant. The drop in cross-reactivity was significantly more pronounced following B.1.1.7 than parental strain infection. Conclusions: The results indicate that heterotypic immunity induced by SARS-CoV-2 variants is asymmetric. Funding: This work was supported by the Francis Crick Institute and the Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg.
Keywords
